Peter Pitts on communicating with FDA
This article was originally published in The Gray Sheet
Executive Summary
Former Associate Commissioner for External Relations will address AdvaMed Medical Technology Communications Conference Oct. 13 in his current role as senior VP-health affairs at New York PR firm Manning, Salvage & Lee. Pitts' luncheon speech will cover the "boundaries of company communications versus FDA communications, best ways to bridge communications gaps with the agency and its use of the Web to promote company advisories," according to an 1agenda for the two-day Washington, D.C. meeting...
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.